A new antitumor antibiotic, named auromomycin, was isolated from the culture broth of St•eptornyces macromomyceticus, a macromomycin-producing strain. The antibiotic was recovered from the culture filtrate by salting out with ammonium sulfate and further purified by successive application of ion-exchange chromatography on Amberlite IRA-93 (Cl form) and DEAF-Sephadex (OH form), Gel filtration on Sephadex G-50 and hydrophobic chromatography on Octyl-Sepharose CL-4B. The antibiotic is an acidic polypeptide with a molecular weight of 12,500 and an isoelectric point of pH 5.4 and consists of 16 different amino acids. It has characteristic absorption maxima at 273 nm and 357 nm in the ultraviolet spectrum and two minima at 280 nm and 350 nm in the optical rotatory dispersion spectrum. Auromomycin exhibits antibacterial activity not only against Gram-positive bacteria, but also Gram-negative bacteria. Antitumor activities of auromomycin were revealed against EHRLICH ascites carcinoma, ascites sarcoma 180, L1210 leukemia and LEWIS lung carcinoma. Auromomycin was found to be converted into macromomycin by adsorption chromatography on Amberlite XAD. During the course of our studies for the production and purification of macromomycin, one active fraction purified from the culture broth of S. macromomyceticus often had a yellow color, while macromomycin was colorless. Therefore we tried to isolate the yellow substance from the culture broth of S. macromomyceticus and obtained a new antibiotic, designated auromomycin, which showed a wider antibacterial spectrum than macromomycin.
A new antitumor antibiotic, named auromomycin, was isolated from the culture broth of St•eptornyces macromomyceticus, a macromomycin-producing strain. The antibiotic was recovered from the culture filtrate by salting out with ammonium sulfate and further purified by successive application of ion-exchange chromatography on Amberlite IRA-93 (Cl form) and DEAF-Sephadex (OH form), Gel filtration on Sephadex G-50 and hydrophobic chromatography on Octyl-Sepharose CL-4B. The antibiotic is an acidic polypeptide with a molecular weight of 12,500 and an isoelectric point of pH 5.4 and consists of 16 different amino acids. It has characteristic absorption maxima at 273 nm and 357 nm in the ultraviolet spectrum and two minima at 280 nm and 350 nm in the optical rotatory dispersion spectrum. Auromomycin exhibits antibacterial activity not only against Gram-positive bacteria, but also Gram-negative bacteria. Antitumor activities of auromomycin were revealed against EHRLICH ascites carcinoma, ascites sarcoma 180, L1210 leukemia and LEWIS lung carcinoma. Auromomycin was found to be converted into macromomycin by adsorption chromatography on Amberlite XAD. demonstrated that macromomycin caused inhibition of DNA synthesis and mitosis, and DNA strand scission.
During the course of our studies for the production and purification of macromomycin, one active fraction purified from the culture broth of S. macromomyceticus often had a yellow color, while macromomycin was colorless. Therefore we tried to isolate the yellow substance from the culture broth of S. macromomyceticus and obtained a new antibiotic, designated auromomycin, which showed a wider antibacterial spectrum than macromomycin.
In this paper, the production, isolation and physicochemical and biological properties of auromomycin, and the conversion of auromomycin into macromomycin are described.
Fermentation
The procedures used are similar to those employed for the production of macromomycin as described previously1,8).
Streptomyces macromomyceticus ATCC 29816 was inoculated into 100 ml of a culture medium containing 1% glucose, 1 % soluble starch, 1.5% soybean powder, 0.1 % dipotassium phosphate, 0.0008% manganese chloride, 0.0002% zinc sulfate and 0.05% antifoamer Disfoam CC-118 (Nippon Oils and Fats Co.) in a 500-m1 Sakaguchi flask. The pH was adjusted to 7.2 before sterilization.
The seed inoculum was grown at 28°C for 2 days on a reciprocal shaker. The cultured broth (90 ml) was transferred to 18 liters of the same medium in ajar fermentor (30 liters volume). The fermentation was continued under aeration of 18 liters/min. at 28°C for 3 days with stirring at 500 rpm. Maximal production of the antibiotic was attained after 6080 hours.
The activity of auromomycin was determined by the cylinder agar plate method using Sarcina lutea and Escherichia co/i as the assay organisms. The nutrient agar medium employed for seed and base layers contained 0.6 % peptone, 0.3 % yeast extract, 0.15 % meat extract, 0.1 % glucose and 1.5 % agar, and the pH was adjusted to 6.7 before sterilization. The diameters of the inhibition zone at the concentration of 0.5 mg/ml aqueous solution of auromomycin were about 20.0 mm and 19.5 mm against S. lutea and E. coli, respectively. During purification, fractions were monitored by the inhibition zone against E. coli, comparing with that of the broth filtrate.
Isolation and Purification
Sixty-four liters of the harvested broth collected from 4 jar fermentors were filtered with filter aid (Dicalite). The filtrate was saturated with ammonium sulfate and allowed to stand at 5°C for 4 hours. Six hundred ml of an aqueous solution containing 265 g of anhydrous sodium carbonate and immediately thereafter, 600 ml of an aqueous solution containing 265 g of ferric chloride hexahydrate as a coagulant were added. The resulting precipitate was collected by continuous centrifugal separation at 5°C and 10,000 rpm. The precipitate (2.2 kg) was dissolved in 13 liters of deionized water. Insoluble material was removed by centrifugal separation and 12.1 liters of the supernatant containing auromomycin were obtained. The column was eluted with 0.2 M Tris-HCl buffer (pH 7.0) to afford 180 ml of the active fraction. The fraction was concentrated with Ultra Filter UH-1 to 70 ml and thereafter subjected to column chromatography on Sephadex G-50 (2 liters, 5.6 x 81 cm) using deionized water as an eluting solvent. The crystals were collected on a glass filter, washed with 10 ml of a 15% aqueous solution of ammonium sulfate and dissolved in 10 ml of deionized water. 
(16 or 17)
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(1) buffer at a flow rate of 35 ml/hour. As shown in Table 1 , it consists of 16 different amino acids, with methionine and arginine absent. One tryptophan residue was found in the auromomycin molecule as determined by N-bromosuccinimide oxidation11). The reduced form of auromomycin was also shown to possess four sulfhydryl groups by p-chloromercuribenzoic acid titration12). This amino acid composition supports a molecular weight of approximately 12,000. The N-terminal amino acid of the antibiotic was identified as alanine by dinitrophenylation13)
Aurornomycin is relatively stable in the pH range of 5-9, but loses its antibacterial activity rapidly in strong acid or alkaline solution. On standing at room temperature both the solid form and aqueous solution of auromomycin gradually lose activity. Both the solid and aqueous solution of the antibiotic are rapidly inactivated by ultraviolet irradiation.
Biological Properties
The antimicrobial spectrum of auromomycin is shown in Table 2 .
The antibiotic in hibited both Effect of auromomycin on survival time of Table 6 and active when administered subcutaneously at the site of tumor inoculation (Table 6 ). In the latter case macromonrycin was more effective than auromomycin and neocarzinostatin. As shown in Table   7 , a single intravenous injection of auromomycin possessed marked activity against LEWIS lung carcinoma implanted intravenously. Treatment with 1.5 mg/kg of auromomycin resulted in survival of all the mice for over 60 days after tumor inoculation. Macrornomycin and neocarzinostatin
were also effective but their activity was less than that of auromomycin.
The LD50 by a single intravenous injection of auromomycin to ddY mice was 3 mg/kg.
Conversion of Auromomycin into Macromomycin
A variety of methods such as adsorption chromatography using silica gel, alumina and Amberlite XAD (Rohm and Haas Co.), ion-exchange chromatography, treatment with acid , alkaline or heat, and irradiation with ultraviolet light were studied for the conversion of auromomycin into macromomycin. Consequently, adsorption chromatography on Amberlite XAD-7 was found to be most suitable. The procedures used are as follows:
Auromomycin (500 mg) was dissolved in 200 ml of an 8 % aqueous solution of ammonium sulfate.
The solution was applied to a column (3 x 21 cm) of Amberlite XAD-7 (150 ml). The column was washed with 200 ml of the 8 % aqueous solution of ammonium sulfate at a flow rate of 450 ml hour and followed immediately by elution with 30% ethanol collecting fractions of 5 ml. The fractions of tube No. 13 -32 which showed antibacterial activity against S. lutea and strong ultraviolet absorption at 280 nm were combined to afford 100 ml. The fraction obtained was concentrated to 60 ml using a rotary evaporator at 40°C under reduced pressure to remove ethanol. The concentrate was placed on a column (5.6 x 81 cm) of Sephadex G-50 (2 liters), and developed with deionized water to obtain 150 ml of an active fraction. This fraction was lyophilized to yield 140 nag of a white powder.
The physicochemical and biological properties of the white powder obtained were compared One hundred mg of auromomycin and 100 mg of macromomycin were dissolved in 30 ml of first eluting buffer (0.1 mM phosphate buffer, pH 7.0, of 40% saturation with ammonium sulfate) and mixed. The solution was added to a column (2x38 cm) of Octyl-Sepharose CL-4B (120 ml).
The column was eluted with the same buffer until peak A was eluted, which required approximately 600 ml of the first eluting buffer, and thereafter, with second eluting buffer (0.1 mM phosphate buffer, pH 7.0, of 20% saturation with ammonium sulfate) until peak B was eluted. The volume of a fraction collected by a fraction collector was 10 ml.
The absorbance at 280 nm (~) and the antibacterial activities against S. lutea (A) and E. coli (O) of the fractions in the eluate were measured. Independently, one hundred and fifty nag of white powder obtained in the present investigation was dissolved in 30 ml of the first eluting buffer, and chromatographed with the same procedures as described above. The absorbance at 280 nm (•) and the antibacterial activities against S. lutea (A) and E. coli (no activity showed) were similarly measured. conversion of auromomycin into the white powder i.e., macromomycin (Fig. 1,4 ). As shown in Fig. 3 , the optical rotatory dispersion spectrum of the powder showed only a single trough with a minimum at 280 nm whereas the minimum at 350 nm in auromomycin disappeared. The ultraviolet absorption and the optical rotatory dispersion spectra of the powder agreed completely with those of macromomycin. There was no difference in the infrared spectra between authentic auromomycin, macromomycin and the powder. As observed with macromomycin, the powder inhibited Grampositive bacteria but exhibited no activity against Gram-negative bacteria, as shown in Table 2 . It was active against L1210 leukemia when 0.2 -6 mg/kg/day was administered intraperitoneally once daily for 5 consecutive days starting 24 hours after the tumor inoculation. The maximal increase of life span was over 70%. The LD50 after a single intravenous injection administered to mice was 35 mg/kg. Fig. 5 shows the elution pattern from chromatography of the mixture of auromomycin and macromomycin and the white powder alone on a column (2 x 38 cm) of Octyl-Sepharose CL-4B (120 ml). Fractions (10 ml) were collected with the elution of two peaks (A and B). The first peak (A) and the second peak (B) contained auromomycin and macromomycin, respectively, which were confirmed by examining the antibacterial activities of the fractions against S. lutea and E. coli. 'These auromomycin and macromomycin can be separated by Octyl-Sepharose CL-4B chromatography and the powder exhibits the same behavior as macromomycin.
The characteristic differences in physicochemical and biological properties between auromomycin, macromomycin and white powder obtained in the present investigation are summarized in Table 8 .
These properties of the white powder differed from those of auromomycin and were the same as those of macromomycin which were determined at the same time and reported previously1, 8, 14) . Therefore, it was identified as macromomycin.
Discussion
White carrying out studies for the purification of macromomycin from culture filtrates of Streptomyces macromomyceticus ATCC 29816, we often experienced that lyophilized macromomycin powders purified by conventional procedures1,8) such as salting out with ammonium sulfate, gel filtration and ion exchange, had a yellow color.
The fact suggested that the strain could produce macromomycin and at the same time another antibiotic. It had been difficult to separate macromomycin and auromomycin, but we succeeded in their separation using Octyl-Sepharose CL-4B (Fig. 5) . Auromomycin forms plate-like yellow crystals, but macromomycin is not crystallized. Auromomycin is very similar to macromomycin in the following properties: molecular weight, isoelectric point and constitutive amino acids. But as summarized in Table 8 , auromomycin is clearly different from macromomycin in the following properties: ultraviolet absorption spectrum, optical rotatory dispersion spectrum, antibacterial activity, effective dose range against L1210 leukemia and the maximal increase in life span, and acute toxicity to mice. Auromomycin is also observed to be different from neocarzinostatin15).
For example, neocarzinostatin does not contain histidine which is present in auromomycin, but contains arginine which is absent in auromornycin. The isoelectric point of neocarzinostatin is pH 3.5, whereas that of auromomycin is pH 5.4. Neocarzinostatin does not inhibit Gram-negative bacteria but auromomycin inhibits these bacteria.
Auromomycin was confirmed to be converted into macromomycin by adsorption chromatography on Amberlite XAD-7. This method is useful for preparation of macromomycin. The application of this chromatography to culture filtrates of Streptonnces macromoinyceticus which contains both auromomycin and macromomycin can also give homogeneous macromomycin. The mechanism of the conversion is not well defined, except the chromophore present in the auromomycin molecule having a maximum ultraviolet absorption at 350-360nm is removed by Amberlite XAD-7 chromatography.
